The Turkish Competition Board has launched a formal investigation into Orzaks İlaç ve Kimya Sanayi Ticaret AŞ (Orzaks İlaç) to assess whether the company has infringed Articles 4 and 6 of Act No. 4054 on the Protection of Competition. The investigation concerns suspected anticompetitive conduct, including the alleged abuse of a dominant position in the market.
According to the authority, Orzaks is suspected of imposing purchasing obligations on pharmacies, requiring the joint stocking of certain product groups, and applying various discount schemes that may restrict competition. The investigation will also examine whether contractual provisions limited the ability of resellers to engage in online sales, potentially foreclosing competing channels and restricting market access.
The decision to open the investigation followed a preliminary inquiry conducted by the Competition Authority. At its meeting on 11 November 2025, the Competition Board reviewed the information and documents gathered during the preliminary phase and concluded that the findings were sufficiently serious to warrant a full investigation. The formal investigation was initiated pursuant to Article 41 of Act No. 4054 under decision number 25-42/1021-M.
Orzaks İlaç was founded in 2004 with the aim of offering natural health products developed through the collaboration of pharmacists, physicians, and investors. The company launched its first products in 2005 and has since expanded its portfolio to nearly 100 products, positioning itself as an innovative player in the health and wellness sector. Orzaks emphasizes the use of patented raw materials, production processes aligned with halal standards, and a focus on product safety and innovation inspired by natural sources.
The opening of an investigation does not constitute a finding of infringement. The Competition Board will now assess whether Orzaks’s commercial practices restricted competition or amounted to an abuse of dominance under Turkish competition law.